Norgine Receives Approval from Swissmedic for PEDMARQSI® to Combat Hearing Loss in Children Norgine's PEDMARQSI® has gained regulatory approval in Switzerland, marking a significant step in preventing cisplatin-induced hearing loss in pediatric patients. This innovative treatment addresses a critical medical need.

Norgine Receives Approval from Swissmedic for PEDMARQSI® to Combat Hearing Loss in Children #None #Norgine #CISPLATIN #PEDMARQSI

Norgine's PEDMARQSI® Approved to Prevent Cisplatin-Induced Hearing Loss in Children Norgine has announced that Swissmedic has approved PEDMARQSI®, the first treatment for preventing cisplatin-induced hearing loss in children, fulfilling an unmet medical need.

Norgine's PEDMARQSI® Approved to Prevent Cisplatin-Induced Hearing Loss in Children #Amsterdam #Switzerland #Norgine #CISPLATIN #PEDMARQSI

Norgine's PEDMARQSI® Receives Swissmedic Approval to Prevent Hearing Loss in Kids Norgine has announced that its drug PEDMARQSI® has received approval from Swissmedic to prevent cisplatin-induced hearing loss in children under 18.

Norgine's PEDMARQSI® Receives Swissmedic Approval to Prevent Hearing Loss in Kids #Amsterdam #Switzerland #Norgine #CISPLATIN #PEDMARQSI®

RPA exhaustion activates SLFN11 to eliminate cells with heightened replication stress - Nature Cell Biology Stanage et al. identify a role for transfer RNA nuclease SLFN11 in replication-stress-induced cell death in cisplatin-treated cells lacking PrimPol. SLFN11 is activated upon single-stranded DNA accumu...

Some chemo sensitivity looks like a tipping point, not a slow slide.

Nature Cell Biology (2025) finds that knocking out PrimPol (replication restart) makes cisplatin much more toxic in SLFN11-high cells. Survival was validated with colony assays quantified on the #GelCount.

#CellBiology #Cisplatin

Scientists identify PKMYT1 as a regulator of #cisplatin sensitivity in #osteosarcoma, showing that PKMYT1‑induced NPM1 S260 phosphorylation enhances #DNARepair and drives #chemoresistance, while combining cisplatin with RP6306 overcomes resistance.

#STTT: doi.org/10.1038/s413...

Can #IntermittentFasting boost #Cisplatin + #Metformin in resistant #OvarianCancer? 🍽️🧬 This new #iScience paper shows it improves response & survival by stressing #CancerMetabolism 🧠💪
🧾 www.cell.com/action/showP...

NanOlogy Launches Innovative Drug Program for Pediatric Brainstem Tumor NanOlogy introduces a groundbreaking drug development initiative targeting DIPG, a rare and aggressive pediatric brain tumor, aiming for clinical trials by late 2026.

NanOlogy Launches Innovative Drug Program for Pediatric Brainstem Tumor #United_States #Fort_Worth #DIPG #NanOlogy #CISPLATIN

FDA approves pembrolizumab with enfortumab vedotin-ejfv On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex,

FDA approves pembrolizumab (Keytruda) with enfortumab vedotin-ejfv (Padcev) as a new neoadjuvant and adjuvant option for adults with muscle-invasive bladder cancer who can’t receive #cisplatin. #TCSC #CancerNews #BladderCancer #Immunotherapy #FDA

www.fda.gov/drugs/resour...

The impact of albumin conjugation on the cytotoxic properties of cisplatin, oxaliplatin and auranofin in cancer cells The role of human serum albumin (HSA) in the delivery of anticancer metallodrugs remains unclear and requires further investigation. To this end, bioconjugates of HSA with the metallodrugs cisplatin (...

#OpenAccess article by Tiziano Marzo 𝘦𝘵 𝘢𝘭.
#UniversityofFlorence

𝐓𝐡𝐞 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐚𝐥𝐛𝐮𝐦𝐢𝐧 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐞 𝐜𝐲𝐭𝐨𝐭𝐨𝐱𝐢𝐜 𝐩𝐫𝐨𝐩𝐞𝐫𝐭𝐢𝐞𝐬 𝐨𝐟 𝐜𝐢𝐬𝐩𝐥𝐚𝐭𝐢𝐧, 𝐨𝐱𝐚𝐥𝐢𝐩𝐥𝐚𝐭𝐢𝐧 𝐚𝐧𝐝 𝐚𝐮𝐫𝐚𝐧𝐨𝐟𝐢𝐧 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐞𝐥𝐥𝐬

#HSA #metallodrugs
#cisplatin #oxaliplatin #auranofin

🔗 doi.org/10.1039/D5QI01487E

Synapse: Your Connection to our MSK Authors.
Meet: Sheron Latcha
Research Focus: Medicine; Attending

Predicting chronic kidney disease after cisplatin treatment using population-level data
synapse.mskcc.org/synapse/work...

#Cisplatin #ChronicKidneyDisease #CKD #Nephrotoxicity #CancerTreatment

October Issue: Conversion to Resection After Neoadjuvant #Gemcitabine , #Cisplatin , and #NabPaclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis

https://rdcu.be/eMq0E

This latest study shows that Yanghe Decoction suppresses #Osteosarcoma (OS) cell processes by inducing #Apoptosis, #MitochondrialDysfunction & boosting #cisplatin sensitivity, promising synergistic approaches to OS treatment. #medsky

#OpenAccess: www.sciencedirect.com/science/arti...

Researchers identify PKMYT1 as a key driver of #cisplatin resistance in #osteosarcoma, showing that PKMYT1-mediated NPM1 phosphorylation disrupts #DNARepair & that inhibiting PKMYT1 with RP6306 synergizes with cisplatin to overcome #chemoresistance.

#STTT: doi.org/10.1038/s413...

Fundamental & Clinical Pharmacology: Vol 39, No 5 Click on the title to browse this issue

FCP October issue now available!

#SFPT #pharmacology #fundamental #clinical #drug #rat #statin #cholesterol #heart #repurposing #pharmacokinetic #antibiotic #cancer #anxiety #brain #therapeutic #neural #cisplatin #genitourinary #integrin #cell

onlinelibrary.wiley.com/toc/14728206...

MSU will receive a 2025 Golden Goose Award for the scientific success and global impact of cisplatin. To read more, click here: innovationcenter.msu.edu/msus-cisplat...

#Cisplatin #CancerResearch #MSU #GoldenGooseAward #ScientificDiscovery #HealthcareInnovation #CuriosityDrivenResearch

Cisplatin – mit der eGFR das Risiko für die Nieren abschätzen Kanadische Analyse

Etwa jede siebte an #Krebs erkrankte Person entwickelt nach einer #Cisplatin-Therapie eine chronische #Nierenerkrankung. Forschende haben nun analysiert, wovon das Risiko abhängt. Ein einfaches Modell könne demnach die klinische Entscheidungsfindung verbessern. #MedSky #Medizin

Cisplatin in Cancer Treatment: Mechanism, Resistance, Toxicity, and Future Directions - OncoDaily Explore how cisplatin, a cornerstone platinum-based chemotherapy, works to treat cancer. Learn about its mechanism of action, clinical applications, resistance pathways, side effects, and future direc...

Cisplatin in Cancer Treatment: Mechanism, Resistance, Toxicity, and Future Directions

oncodaily.com/drugs/cispla...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Cisplatin #Immunotherapy #Mechanism #Pharmacology #Resistance #Toxicity

The NCCN templates are not hugely prescriptive but for a 75mg/m² regime I just checked, they say 1-3L hydration but only suggest 4mmol (1g) per L.

I'm always surprised US doctors are not sued more.

#OncoPharm #Cisplatin #Magnesium

#IntravitalImaging #PeritubularMicrocirculation #Cisplatin 🐭 #AcuteKidneyInjury
2 mD FITC-dextran DiD-RBC▶️vessel
4 kD TMR-dextran▶️tubule

Microvascular failure precedes renal damage biomarker

CD11b Ab➡️inhibit myeloid cells➡️rescue flow

@jci-insight.bsky.social 2025
insight.jci.org/articles/vie...

Repression of peroxisome proliferation-activated receptor γ coactivator-1α by p53 after #kidneyinjury promotes mitochondrial damage and maladaptive #kidney repair

doi.org/10.1016/j.kint.2025.02.009

#MedSky #NephSky #renalfibrosis #kidneyfibrosis #cisplatin #aki #acutekidneyinjury

Please join us for the Jeff Agar's presentation at Proteoform Thursday March 20 - "Intact Mass Assay Determines Covalent Drug-Target Binding and PK/PD Parameters” #proteomics #ALS #Cisplatin us06web.zoom.us/meeting/regi...

Early and Sensitive Detection of #Cisplatin Induced #KidneyInjury Using Novel #Biomarkers

#VisualAbstract by @jmteakell

www.kireports.org/ar...

🚀 Key #UrothelialCancer abstracts from #ASCOGU!
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.

Combating Chemotherapy Resistance in Cancer Study reveals opportunities to improve effectiveness of common chemotherapy drug

A new study from Cedars-Sinai Cancer and the University of Colorado Anschutz Medical Campus reveals a potential way to overcome tumour resistance to a common chemotherapy drug called cisplatin.#TCSC #cisplatin #chemotherapy

www.cancerhealth.com/article/canc...

🧵1/ Cisplatin has been a cancer-fighting drug for over 50 years, but it comes with a significant risk: #AKI. Let’s dive into cisplatin-associated AKI (CP-AKI). #Cisplatin #Onconephrology @onconephsociety

@ILCAnews breakthrough in #CCA May be combo cytolytic/ICC combo #gemcitabin #cisplatin #durvalumab which appears to offer OS and PFS benefit

Hey #cancer cells! KI's Lippard Lab says resistance to #cisplatin is futile. They're so #metal.via @MITnews)

mitne.ws/1aZLUkF